US Stem Cell Inc
OTC:USRM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
US Stem Cell Inc
Total Current Assets
US Stem Cell Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
US Stem Cell Inc
OTC:USRM
|
Total Current Assets
$68k
|
CAGR 3-Years
1%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
-5%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$29.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$29.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$11.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Assets
$18B
|
CAGR 3-Years
4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
US Stem Cell Inc
Glance View
U.S.Stem Cell, Inc. is a biotechnology company, which focuses on the discovery, development, and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The company is headquartered in Sunrise, Florida. The company went IPO on 2008-02-19. Stem Cell, Inc. is a biotechnology company that is focused on the discovery, development and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of disease and injury. Its MyoCell and MyoCell SDF-1 product candidates are autologous muscle-derived cellular therapies designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. Its Adipocell product is a cell therapy with a range of treatment applications using autologous adipose cells. The firm's business includes the development of cell therapy products, distribution of regenerative medicine products, as well as physician and patient-based regenerative medicine/cell therapy training services. The firm operates through its US Stem Cell Training, Inc. (SCT) and Vet biologics (VBI) divisions.
See Also
What is US Stem Cell Inc's Total Current Assets?
Total Current Assets
68k
USD
Based on the financial report for Dec 31, 2022, US Stem Cell Inc's Total Current Assets amounts to 68k USD.
What is US Stem Cell Inc's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
-5%
Over the last year, the Total Current Assets growth was 33%. The average annual Total Current Assets growth rates for US Stem Cell Inc have been 1% over the past three years , -43% over the past five years , and -5% over the past ten years .
